Valsartan
- Generic Name
- Valsartan
- Brand Names
- Dafiro, Diovan, Diovan Hct, Entresto, Exforge, Exforge Hct
- Drug Type
- Small Molecule
- Chemical Formula
- C24H29N5O3
- CAS Number
- 137862-53-4
- Unique Ingredient Identifier
- 80M03YXJ7I
- Background
Valsartan belongs to the angiotensin II receptor blocker (ARB) family of drugs, which also includes telmisartan, candesartan, losartan, olmesartan, and irbesartan. ARBs selectively bind to angiotensin receptor 1 (AT1) and prevent the protein angiotensin II from binding and exerting its hypertensive effects, which include vasoconstriction, stimulation and syn...
- Indication
Valsartan is indicated for the treatment of hypertension to reduce the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. It is also indicated for the treatment of heart failure (NYHA class II-IV) and for left ventricular dysfunction or failure after myocardial infarction when the use of an angiotensin-converting ...
- Associated Conditions
- Cardiovascular Mortality, Diabetic Nephropathy, Heart Failure, Hypertension, Moderate Essential Hypertension, Chronic heart failure with reduced ejection fraction (NYHA Class II), Chronic heart failure with reduced ejection fraction (NYHA Class III), Chronic heart failure with reduced ejection fraction (NYHA Class IV), Hospitalization due to cardiac failure
- Associated Therapies
- -
Efficacy of a Combination of Amlodipine/Valsartan on 24H Blood Pressure Control With One Nocturnal or Diurnal Intake a Day
- First Posted Date
- 2008-06-18
- Last Posted Date
- 2011-05-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 478
- Registration Number
- NCT00700271
- Locations
- 🇹🇳
Investigative sites in Tunisia, Tunisia, Tunisia
🇫🇷Investigative sites in France, Paris, France
Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Compared to Valsartan Monotherapy or Hydrochlorothiazide Monotherapy in Elderly (>70) With Mild-moderate Hypertension.
- First Posted Date
- 2008-06-17
- Last Posted Date
- 2011-04-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 384
- Registration Number
- NCT00698646
- Locations
- 🇺🇸
Investigative Site, Taylors, South Carolina, United States
🇺🇸Investigative Sites, Pismo Beach, California, United States
🇺🇸Investigative site, St George, Utah, United States
An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.
- Conditions
- Interventions
- First Posted Date
- 2008-06-12
- Last Posted Date
- 2011-04-19
- Lead Sponsor
- Takeda
- Target Recruit Count
- 1291
- Registration Number
- NCT00696436
Black Education and Treatment of Hypertension (BEAT HTN)
- First Posted Date
- 2008-04-21
- Last Posted Date
- 2012-12-04
- Lead Sponsor
- Creighton University
- Target Recruit Count
- 99
- Registration Number
- NCT00661895
- Locations
- 🇺🇸
Creighton Community Health Center, Omaha, Nebraska, United States
Cardioprotective Benefits of Carvedilol-CR or Valsartan Added to Lisinopril
- First Posted Date
- 2008-04-14
- Last Posted Date
- 2022-05-27
- Lead Sponsor
- State University of New York at Buffalo
- Target Recruit Count
- 30
- Registration Number
- NCT00657241
- Locations
- 🇺🇸
Erie County Medical Center, Buffalo, New York, United States
Probucol Combined With Valsartan in Reducing Proteinuria in Diabetes Nephropathy
- Conditions
- Interventions
- First Posted Date
- 2008-04-09
- Last Posted Date
- 2016-08-24
- Lead Sponsor
- Guangdong Provincial People's Hospital
- Target Recruit Count
- 170
- Registration Number
- NCT00655330
- Locations
- 🇨🇳
Guangdong General Hospital, Guangzhou, Guangdong, China
Blood Pressure Lowering in Acute Stroke Trial (BLAST)
- Conditions
- First Posted Date
- 2008-03-04
- Last Posted Date
- 2016-04-14
- Lead Sponsor
- Stanford University
- Registration Number
- NCT00627991
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Comparison of Effects of Telmisartan and Valsartan on Neointima Volume in Diabetes
- Conditions
- Interventions
- First Posted Date
- 2008-01-24
- Last Posted Date
- 2015-09-03
- Lead Sponsor
- Korea University Anam Hospital
- Target Recruit Count
- 72
- Registration Number
- NCT00599885
- Locations
- 🇰🇷
Korea University Anam Hospital, Seoul, Korea, Republic of
Efficacy and Safety Comparison of Azilsartan Medoxomil to Valsartan in Participants With Essential Hypertension
- First Posted Date
- 2008-01-11
- Last Posted Date
- 2012-02-02
- Lead Sponsor
- Takeda
- Target Recruit Count
- 984
- Registration Number
- NCT00591578
Valsartan for Suppression of Plaque Volume and Restenosis After Drug-Eluting Stent
- First Posted Date
- 2008-01-10
- Last Posted Date
- 2012-08-08
- Lead Sponsor
- Seung-Jung Park
- Target Recruit Count
- 220
- Registration Number
- NCT00589732
- Locations
- 🇰🇷
St. Mary's Catholic Medical Center, Seoul, Korea, Republic of
🇰🇷Asan Medical Center, Seoul, Korea, Republic of
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.